Centene’s second quarter was marked by clear operational improvements, yet the market reacted negatively, reflecting concerns about underlying trends. Management attributed the quarter’s outperformance to disciplined cost management and favorable risk adjustment in its Marketplace and Medicare businesses. CEO Sarah London cited enhanced execution in quality initiatives and efficiency gains, while noting that Medicaid membership declines were sharper than anticipated, largely due to state-driven eligibility tightening and preparation for regulatory changes.
Is now the time to buy CNC? Find out in our full research report (it’s free for active Edge members).
Centene (CNC) Q2 CY2026 Highlights:
- Revenue: $53.58 billion vs analyst estimates of $47.39 billion (9.9% year-on-year growth, 13.1% beat)
- Adjusted EPS: $2.51 vs analyst estimates of $1.08 (significant beat)
- The company lifted its revenue guidance for the full year to $195.5 billion at the midpoint from $189.5 billion, a 3.2% increase
- Management raised its full-year Adjusted EPS guidance to $4.80 at the midpoint, a 41.2% increase
- Operating Margin: 2.2%, up from -0.9% in the same quarter last year
- Customers: 25.89 million, down from 26.27 million in the previous quarter
- Market Capitalization: $31.5 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Centene’s Q2 Earnings Call
- John Stansel (J.P. Morgan) asked about high-acuity Medicaid attrition and whether recent declines are a pull-forward of OB3 impacts. CEO Sarah London explained that state tightening and eligibility reviews are likely accelerating some attrition and that management is working closely with states to minimize unnecessary disruption.
- Ann Hynes (Mizuho) questioned prospects for Medicaid margin expansion amid regulatory changes. London said margin recovery remains the goal, noting a more manageable population mix and better data/tools compared to the pandemic-era redeterminations process.
- Justin Lake (Wolfe Research) pressed for clarity on the mechanics of Marketplace risk adjustment settlements. CFO Drew Asher detailed how recurring and nonrecurring components affect reported margins and provided context on risk adjustment assumptions for the year.
- Andrew Mok (UBS) asked about 2027 Marketplace pricing and growth prospects. London said Centene’s focus remains on balanced portfolio strategy and margin restoration, with growth expectations dependent on policy stability and competitive dynamics.
- Sarah James (Barclays) probed the practical implications of AI investments and their impact on G&A ratios. London emphasized a disciplined approach, prioritizing high-return use cases and foundational data capabilities over broad, unfocused spending.
Catalysts in Upcoming Quarters
In the coming quarters, the StockStory team will be watching (1) the pace and impact of Medicaid membership attrition as OB3 requirements are phased in, (2) Centene’s ability to achieve further cost efficiencies through AI and operational streamlining, and (3) execution on Marketplace margin targets despite ongoing policy and risk adjustment uncertainties. Success will also depend on maintaining constructive state partnerships and adapting to evolving regulatory landscapes.
Centene currently trades at $64.27, in line with $64.08 just before the earnings. Is there an opportunity in the stock? Find out in our full research report (it’s free).
Our Favorite Stocks Right Now
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.